Rivastigmine NDC 70771-1951

NDC codes

FDA NDC Directory

Product NDC (as listed)70771-1951Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70771-1951Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70771-1951-7	70771195107	30 POUCH in 1 CARTON (70771-1951-7) / 24 h in 1 POUCH (70771-1951-1)Marketed from Mar 6, 2019

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rivastigmine
Generic name (nonproprietary): rivastigmine
Active ingredients: Rivastigmine — 13.3 mg/24h
Dosage form: Patch, Extended release
Route: Transdermal
Labeler: Zydus Lifesciences Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 206318
Marketing start: Mar 6, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Cholinesterase Inhibitors (Mechanism)
Identifiers: Product ID 70771-1951_eb52b342-1672-42e7-bb4c-9c8f1bce7fc3SPL ID eb52b342-1672-42e7-bb4c-9c8f1bce7fc3SPL set ID 966d59ea-5cea-4fef-8b96-e0efe885caf4RxCUI 725021, 725023, 1308569UNII PKI06M3IW0
Pharmacologic class: Cholinesterase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Transdermal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470771195107 followed by a unit qualifier and the quantity

Package 70771-1951-07. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 17, 2025.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 206318

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 206318
Product	Strength	Form · route	Labeler	Product NDC
Rivastigmine	Rivastigmine 9.5 mg/24h	Patch, Extended releaseTransdermal	Northstar Rx LLC.	16714-116
Rivastigmine	Rivastigmine 4.6 mg/24h	Patch, Extended releaseTransdermal	Zydus Lifesciences Limited	70771-1949
Rivastigmine	Rivastigmine 9.5 mg/24h	Patch, Extended releaseTransdermal	Zydus Lifesciences Limited	70771-1950
Rivastigmine	Rivastigmine 4.6 mg/24h	Patch, Extended releaseTransdermal	Zydus Pharmaceuticals USA Inc.	70710-1196
Rivastigmine	Rivastigmine 9.5 mg/24h	Patch, Extended releaseTransdermal	Zydus Pharmaceuticals USA Inc.	70710-1197
Rivastigmine	Rivastigmine 13.3 mg/24h	Patch, Extended releaseTransdermal	Zydus Pharmaceuticals USA Inc.	70710-1198
Rivastigmine	Rivastigmine 13.3 mg/24h	Patch, Extended releaseTransdermal	Northstar Rx LLC.	16714-117